220 related articles for article (PubMed ID: 28583379)
1. Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement.
Quintanal-Villalonga Á; Carranza-Carranza A; Meléndez R; Ferrer I; Molina-Pinelo S; Paz-Ares L
Clin Lung Cancer; 2017 Nov; 18(6):667-674.e1. PubMed ID: 28583379
[TBL] [Abstract][Full Text] [Related]
2. The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction.
Quintanal-Villalonga Á; Ojeda-Márquez L; Marrugal Á; Yagüe P; Ponce-Aix S; Salinas A; Carnero A; Ferrer I; Molina-Pinelo S; Paz-Ares L
Sci Rep; 2018 Feb; 8(1):2394. PubMed ID: 29402970
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer.
Marmé F; Hielscher T; Hug S; Bondong S; Zeillinger R; Castillo-Tong DC; Sehouli J; Braicu I; Vergote I; Isabella C; Mahner S; Ferschke I; Rom J; Sohn C; Schneeweiss A; Altevogt P
Int J Cancer; 2012 Aug; 131(4):E586-91. PubMed ID: 22034009
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of morphologic findings for lung squamous cell carcinoma patients.
Gürel D; Ulukuş Ç; Karaçam V; Ellidokuz H; Umay C; Öztop İ; Sarıoğlu S
Pathol Res Pract; 2016 Jan; 212(1):1-9. PubMed ID: 26608418
[TBL] [Abstract][Full Text] [Related]
5. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung.
Falvella FS; Frullanti E; Galvan A; Spinola M; Noci S; De Cecco L; Nosotti M; Santambrogio L; Incarbone M; Alloisio M; Calabrò E; Pastorino U; Skaug V; Haugen A; Taioli E; Dragani TA
Int J Cancer; 2009 Jun; 124(12):2880-5. PubMed ID: 19296538
[TBL] [Abstract][Full Text] [Related]
6. FGFR4 Is a Potential Predictive Biomarker in Oral and Oropharyngeal Squamous Cell Carcinoma.
Koole K; van Kempen PM; van Bockel LW; Smets T; van der Klooster Z; Dutman AC; Peeters T; Koole R; van Diest P; van Es RJ; Willems SM
Pathobiology; 2015; 82(6):280-9. PubMed ID: 26551585
[TBL] [Abstract][Full Text] [Related]
7. FGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx.
Dutra RL; de Carvalho MB; Dos Santos M; Mercante AM; Gazito D; de Cicco R; Group G; Tajara EH; Louro ID; da Silva AM
PLoS One; 2012; 7(11):e50747. PubMed ID: 23226373
[TBL] [Abstract][Full Text] [Related]
8. ECRG1 and FGFR4 single nucleotide polymorphism as predictive factors for nodal metastasis in oral squamous cell carcinoma.
Choi KY; Rho YS; Kwon KH; Chung EJ; Kim JH; Park IS; Lee DJ
Cancer Biomark; 2012-2013; 12(3):115-24. PubMed ID: 23481570
[TBL] [Abstract][Full Text] [Related]
9. Association of lymph node involvement with the prognosis of pathological T1 invasive non-small cell lung cancer.
Zhang YK; Chai ZD; Tan LL; Wang ZY; Chen ZJ; Le HB; Zhu WY
World J Surg Oncol; 2017 Mar; 15(1):64. PubMed ID: 28302176
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
[TBL] [Abstract][Full Text] [Related]
11. FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.
Marmé F; Werft W; Benner A; Burwinkel B; Sinn P; Sohn C; Lichter P; Hahn M; Schneeweiss A
Ann Oncol; 2010 Aug; 21(8):1636-1642. PubMed ID: 20147743
[TBL] [Abstract][Full Text] [Related]
12. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of fibroblast growth factor receptor 4 polymorphisms in primary breast cancer.
Wei W; You Z; Sun S; Wang Y; Zhang X; Pang D; Jiang Y
Mol Carcinog; 2018 Aug; 57(8):988-996. PubMed ID: 29603419
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer.
Sasaki H; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
Oncol Rep; 2008 Nov; 20(5):1125-30. PubMed ID: 18949411
[TBL] [Abstract][Full Text] [Related]
15.
Cho SH; Hong CS; Kim HN; Shin MH; Kim KR; Shim HJ; Hwang JE; Bae WK; Chung IJ
Cancer Res Treat; 2017 Jul; 49(3):766-777. PubMed ID: 27857023
[TBL] [Abstract][Full Text] [Related]
16. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.
Hu L; Cong L
Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.
Lim SH; Sun JM; Choi YL; Kim HR; Ahn S; Lee JY; Lee SH; Ahn JS; Park K; Kim JH; Cho BC; Ahn MJ
Cancer; 2016 Oct; 122(19):3024-31. PubMed ID: 27315356
[TBL] [Abstract][Full Text] [Related]
19. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.
Liu K; Chen HL; Gu MM; You QS
Int J Clin Exp Pathol; 2015; 8(12):16081-8. PubMed ID: 26884885
[TBL] [Abstract][Full Text] [Related]
20. Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer.
Shah A; Swain WA; Richardson D; Edwards J; Stewart DJ; Richardson CM; Swinson DE; Patel D; Jones JL; O'Byrne KJ
Clin Cancer Res; 2005 Apr; 11(8):2930-6. PubMed ID: 15837744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
